Boston Scientific reached a new 1-year high at $74.39 after reporting better-than-expected Q1 earnings, with revenue of $3.86B and an adjusted EPS of $0.56.
Boston Scientific (NYSE:BSX) reached a new 1-year high at $74.39 on Wednesday. The company reported better-than-expected first-quarter earnings, generating $3.86 billion in revenue and an adjusted EPS of $0.56. Boston Scientific's Cardiovascular segment led with $2.4 billion in sales, rising 15.9%. MedSurg also saw significant growth, with revenues of over $1.4 billion, up 10.3%. The company's strong quarterly performance led to an increase in its annual profit forecast, with adjusted earnings expected to range between $2.29 and $2.34 per share.
April 24, 2024
13 Articles